lobbying_activities: 3191763

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
3191763	c1abc650-eef3-4f9f-aa2b-81c860415893	Q2	THE OB-C GROUP, LLC	29802	EMERGENT BIOSOLUTIONS INC.	2024	second_quarter	DIS	* Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act * No Specific Bill Number. Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield * No Specific Bill Number. Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines * No Specific Bill Number. State opioid response (SOR) Grant Funding. * No Specific Bill Number. Substance Abuse and Mental Health Block Grants (SABG) funding. * NDAA for Fiscal Year 2024-provisions related to biological and chemical defense and access to naloxone.	HOUSE OF REPRESENTATIVES,SENATE	20000		0	0	2024-07-15T12:17:54-04:00